Goggin

FDA Calendar Extreme Trades: 85 Single Digit Stocks

Keep and eye on GWP (GWPRF) for its application to the FDA for approval this fall or winter. On London's AIM.

Pending Clinical Trial Results: Ten Extreme Trades

GW Pharmaceutical (GWPRF) is in a Phase III trial in the US for treating cancer pain with its marijuana-derived non-smoked drug Sativex. Very thinly traded in the US, it is on London's AIM market. Fascinating information on this use and others, some already approved internationally is at their website gwpharma.com.
Disclorsure: I own GWPRF.